Webinar: Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies

Our webinar “Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies” was live at 12PM EDT on March 27, 2024.

About the webinar:

Atopic Dermatitis is a chronic inflammatory skin condition characterized by redness, cracking, and scaling, often leading to painful sores. While the precise cause of AD remains unclear, a dysfunctional epidermal barrier and dysregulated immune responses (including IL-4, IL-13, IL-25, IL-33, and IFN-g) are thought to influence the onset and severity of the disease. Various therapeutic options, encompassing both topical and systemic immunosuppressants, are employed to manage AD symptoms. However, the need for more targeted and personalized treatments remains.

To advance our understanding of the determinants of AD and explore new treatments, numerous translational animal models have been established to recapitulate disease symptoms and profile changes in immune cell subtypes in response to novel therapeutic candidates. In this webinar, we will review the underlying mechanisms of these models, explore their advantages, and offer insights into their potential use based on specific research objectives.

Date and Time

March 27, 2024, 12:00 PM EDT

Speaker

Luke Yu, MD, Ph.D

Global head of Preclinical Pharmacology, Biocytogen Boston Corp & Biocytogen Pharmaceuticals

Moderator

Jenna Frame, Ph.D.

Sr. Manager, Scientific Communications & Marketing, Biocytogen Boston Corp.

Watch the webinar recording: Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies